Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Capital Expenditures (2020 - 2022)

Guided Therapeutics (GTHP) has disclosed Capital Expenditures for 8 consecutive years, with $3000.0 as the latest value for Q4 2022.

  • Quarterly Capital Expenditures fell 25.0% to $3000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $3000.0 through Sep 2023, down 90.62% year-over-year, with the annual reading at $2000.0 for FY2025, N/A changed from the prior year.
  • Capital Expenditures hit $3000.0 in Q4 2022 for Guided Therapeutics, up from -$3000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $17000.0 in Q2 2022 to a low of -$3000.0 in Q3 2022.
  • Historically, Capital Expenditures has averaged $5111.1 across 3 years, with a median of $4000.0 in 2021.
  • Biggest YoY gain for Capital Expenditures was 1300.0% in 2022; the steepest drop was 160.0% in 2022.
  • Year by year, Capital Expenditures stood at $1000.0 in 2020, then skyrocketed by 300.0% to $4000.0 in 2021, then dropped by 25.0% to $3000.0 in 2022.
  • Business Quant data shows Capital Expenditures for GTHP at $3000.0 in Q4 2022, -$3000.0 in Q3 2022, and $17000.0 in Q2 2022.